Business Wire

GALDERMA

20.9.2022 10:01:42 CEST | Business Wire | Press release

Share
Galderma Debuts The Sensitive Skincare Faculty, a Global Expert Group to Improve Understanding and Management of Sensitive Skin

Reinforcing its commitment to advancing dermatology for every skin story, Galderma announced today the formation of a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives through focusing on three key pillars of research, innovation and engagement that play a key role in improving the broad understanding and management of sensitive skin. Comprised of 13 experts from across the world, the group will have representation from diverse geographies including China, Brazil, the Philippines, Germany, France, Australia, Italy and the United States (U.S.).

 

“We want people to feel in control of their skin, and this is especially important for those who have skin conditions that are often misunderstood – like sensitive skin.
We’re delighted to bring together such an esteemed group of experts from around the world who will collaborate to propose and implement research, innovation and educational projects
to advance the science of sensitive skin and bring positive changes to the whole community.”

 

WALTER GEIGER
CONSUMER CARE GLOBAL BUSINESS UNIT HEAD, GALDERMA

 

Sensitive skin is a complex and often interconnected condition, requiring personalized care and products specifically designed for it. More than seventy percent of people worldwide diagnose themselves as having sensitive skin, which can negatively impact quality of life and leave them feeling frustrated and looking for better solutions.i There is a need for science-backed guidance and advice on how to identify and care for sensitive skin of all kinds, to help improve the overall quality of sensitive skin.

The Sensitive Skincare Faculty will focus on three core pillars of activities:

  • Research – expanding the understanding of sensitive skin by filling evidence gaps and advancing in emerging areas
  • Innovation – inspiring the development of new solutions to improve diagnosis and care
  • Engagement – enhancing the knowledge of healthcare professionals to shape the future of best practice

In partnership with the Department of Dermatology at the George Washington University School of Medicine and Health Sciences, two grants have been awarded to accelerate the mission of the Sensitive Skincare Faculty. The first will establish a Galderma Sensitive Skin Translational Research Fellowship Program over five years to support medical students interested in expanding their research skill set into sensitive skin. The second project, the Galderma Skin Research Acceleration Fund, will span two years and look specifically at establishing a standard definition of sensitive skin.

 

“Our goal is to transform the science of sensitive skin into actionable insights and practical advice
that will empower everyone – from consumers and patients to healthcare professionals – to make positive strides forward.
We’re bringing together the latest information backed by science and making it available and accessible to everyone who needs it.”

 

PROFESSOR ADAM FRIEDMAN
CO-CHAIR, SENSITIVE SKINCARE FACULTY,
PROFESSOR AND CHAIR OF DERMATOLOGY,
THE GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES

 

Faculty members include Adam Friedman (co-chair, U.S.), Giovanni Pellacani (Italy), Martina Kerscher (Germany), Aaron Farberg (U.S.), Flávia Alvim Sant’Anna Addor (Brazil), Belinda Welsh (Australia), Yan Wu (China), Flordeliz Abad-Casintahan (Philippines), Adelaide Hebert (U.S.), Xiang Leihong (China), Laurent Misery (France), Joachim Fluhr (Germany) and Leona Yip (Australia).

The faculty’s inaugural meeting took place at the European Academy of Dermatology and Venereology congress in Milan, where members also participated in a Galderma-sponsored symposium on sensitive skin insights and management approaches.

About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:
iChen W, Dai R, Li L. The prevalence of self‐declared sensitive skin: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2020 Aug;34(8):1779-88.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005039/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st

Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release

Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an

Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release

Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai

Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release

– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye